What Routine Monitoring Looks Like for Lurbinectedin
Routine monitoring for lurbinectedin (Yondelis), used to treat metastatic small cell lung cancer, focuses on detecting myelosuppression, hepatotoxicity, and other effects early. Patients receive it intravenously every 21 days, with checks before each cycle.[1]
Blood Counts and Bone Marrow Checks Before Each Dose
Complete blood counts (CBC) with differentials are required within 48 hours prior to each dose. Treatment delays or dose reductions occur if:
- Absolute neutrophil count <1,500/μL
- Platelets <100,000/μL
- Hemoglobin <9 g/dL
Granulocyte colony-stimulating factors (G-CSF) are recommended for secondary prophylaxis after neutropenia.[1]
Liver Function Tests Timing and Thresholds
Assess liver function tests (ALT, AST, bilirubin, alkaline phosphatase) before each cycle. Withhold or reduce dose for:
- Total bilirubin > upper limit of normal (ULN)
- ALT or AST >3x ULN (or >5x if baseline elevated)
Monitor closely in patients with hepatic impairment.[1]
What Happens During and After Infusion
Administer over 60 minutes with dexamethasone premedication to reduce nausea. Monitor for hypersensitivity during infusion. Post-treatment, track for rhabdomyolysis (via CPK levels if symptoms like muscle pain occur) and tumor lysis syndrome in high-burden cases.[1]
Patient-Reported Symptoms to Watch
Advise reporting fatigue, nausea, diarrhea, or unusual bleeding promptly. Weekly CBCs may be needed during the first two cycles if counts drop significantly.[1]
How Monitoring Differs for Hepatic Impairment
For bilirubin >1.5-3x ULN or Child-Pugh B, use reduced dosing (1 mg/m²) with intensified LFT monitoring. Avoid in Child-Pugh C.[1]
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209924s004lbl.pdf (Yondelis Prescribing Information)